BUSINESS● LOWJul 21 · Jul 21, 2026, 11:00 AM
US biotech firm developing therapies for infant brain injuries plans Hong Kong listing
South China Morning Post
A US-headquartered biotech firm plans to seek a primary listing in Hong Kong, joining a swelling pipeline of artificial intelligence-powered medical players raising capital in the city. Axiom Biosciences, which develops experimental therapies for newborns with severe brain injuries by using AI, is targeting at least US$200 million through an initial public offering (IPO) in Hong Kong in 2027, followed by a secondary listing in the US in 2029. “Some of the most important science in the world is...
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS24m agoChina, India could face up to 100% U.S. tariffs for buying Russian oilSeeking Alpha TechBUSINESS27m agoBank of England keeps its policy rate unchanged at 3.75%Seeking Alpha Tech